MedTrace Logo

An Evaluation of Immunogenicity and Safety of Two Doses of MVA-nef vs. MVA-BN in HIV-1 Infected Patients

NCT00189930 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 77

Last updated 2012-10-01

No results posted yet for this study

Summary

The objective of the study is to compare two doses of MVA-nef vs. MVA-BN to induce Nef-specific cellular immune response in HIV-1 infected patients

Conditions

  • HIV Infection

Interventions

BIOLOGICAL

MVA-nef

3 imm.: 5E8\_TCID50 MVA-nef, 1E8\_TCID50 MVA-nef in non-dominant upper arm

BIOLOGICAL

IMVAMUNE

3 immunizations: 1E8\_TCID50 IMVAMUNE

Sponsors & Collaborators

  • National Institutes of Health (NIH)

    collaborator NIH

  • Bavarian Nordic

    lead INDUSTRY

Principal Investigators

  • Thomas Harrer, MD · University of Erlangen, Germany

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-04-30
Completion
2006-12-31

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00189930 on ClinicalTrials.gov